ArticleCanadian family physician Medecin de famille canadien2017
First-line medications for alcohol use disorders among public drug plan beneficiaries in Ontario.
Article in Canadian family physician Medecin de famille canadien, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2023Guideline
- Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-analysis.Journal of addiction medicinePooled it
- Facilitating rapid access to addiction treatment: a randomized controlled trial.Addiction science & clinical practice · 2021Trial
- Article
- Prevalence and Correlates of Reporting a Gabapentin Prescription for Pain Among People Who Use Opioids: A Longitudinal Community-Recruited Study.Drug and alcohol review · 2026Article
- Circumstances surrounding alcohol toxicity deaths and prior pharmacotherapy for alcohol use disorder in Ontario, Canada.Alcohol and alcoholism (Oxford, Oxfordshire) · 2025Article
- Innovations to the ECHO model to enhance reach and network-building among addiction clinicians in Western Canada.Addiction science & clinical practice · 2024Article
- Rethinking Substance Use as Social History: Charting a Way Forward.Journal of general internal medicine · 2024Article
- Article
- Outcomes in Clinical Subgroups of Patients With Alcohol-Related Hospitalizations.JAMA network open · 2024Article
- Changes in health service use due to alcohol during the COVID-19 pandemic among individuals with and individuals without pre-existing alcohol-related medical diagnoses.Canadian journal of public health = Revue canadienne de sante publique · 2023Article
- Hazardous drinking and alcohol use disorders.Nature reviews. Disease primers · 2022Review
- Trends in the Use of Naltrexone for Addiction Treatment among Alcohol Use Disorder Admissions in U.S. Substance Use Treatment Facilities.International journal of environmental research and public health · 2021Article
- Use of pharmacotherapy for alcohol use disorder in Manitoba, Canada: A whole-population cohort study.PloS one · 2021Article
- A rapid access to addiction medicine clinic facilitates treatment of substance use disorder and reduces substance use.Substance abuse treatment, prevention, and policy · 2020Article
- Receipt of pharmacotherapy for alcohol use disorder by justice-involved women in the Veterans Health Administration.Addiction science & clinical practice · 2019Article
- Improving the quality of health care in Canada.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2018Article
- Trend in Prescription Medication Utilization for Opioid Use Disorder and Alcohol Use Disorder From 2015 to 2021: A Population-wide Study in a Canadian Province.Journal of addiction medicineObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo examine use of first-line alcohol use disorder (AUD) medications (naltrexone and acamprosate) among public drug plan beneficiaries in the year following an AUD diagnosis.
designRetrospective population-based cohort study.
settingOntario.
participantsIndividuals eligible for public drug plan benefits who had an AUD diagnosis at a hospital visit between April 1, 2011, and March 31, 2012.
main outcome measuresNumber of AUD medications dispensed to public drug plan beneficiaries who had a recent hospital visit with an AUD diagnosis, and number of prescriptions dispensed per person.
resultsA total of 10 394 Ontarians between 18 and 65 years of age were identified who had a hospital visit with an AUD diagnosis and were eligible for public drug plan benefits. The rate of AUD medications dispensed in the subsequent year was 3.56 per 1000 population (95% CI 2.51 to 4.91; n = 37). This rate did not differ significantly by sex (
conclusionVery few public drug plan beneficiaries are dispensed first-line AUD medications in the year following an AUD diagnosis.
Indexed as
Identifiers
28500210PMC5429069What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.